Transcutaneous ultrasound-facilitated coronary thrombolysis during acute myocardial infarction.
In preclinical experiments, the combination of transcutaneous, low-frequency ultrasound and thrombolytic therapy has shown improved patency rates over thrombolytics alone. A total of 25 patients with myocardial infarction were treated with a thrombolytic agent and adjunctive transcutaneous ultrasound. No unanticipated major adverse events were observed.
Cohen
Mauricio G
MG
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tuero
Enrique
E
Bluguermann
Jorge
J
Kevorkian
Rubén
R
Berrocal
Daniel H
DH
Carlevaro
Oscar
O
Picabea
Eduardo
E
Hudson
Michael P
MP
Siegel
Robert J
RJ
Douthat
Lori
L
Greenbaum
Adam B
AB
Echt
Debra
D
Weaver
W Douglas
WD
Grinfeld
Liliana R
LR
D003131:Combined Modality Therapy; D017023:Coronary Angiography; D003326:Coronary Circulation; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D000077785:Tenecteplase; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014464:Ultrasonic Therapy / Q000009:adverse effects / Q000379:methods
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase